A detailed history of Manufacturers Life Insurance Company, The transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Manufacturers Life Insurance Company, The holds 24,732 shares of VRDN stock, worth $535,200. This represents 0.0% of its overall portfolio holdings.

Number of Shares
24,732
Previous 31,687 21.95%
Holding current value
$535,200
Previous $412,000 36.41%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$12.16 - $23.33 $84,572 - $162,260
-6,955 Reduced 21.95%
24,732 $562,000
Q2 2024

Aug 14, 2024

BUY
$11.6 - $17.26 $86,420 - $128,587
7,450 Added 30.74%
31,687 $412,000
Q1 2024

May 14, 2024

BUY
$17.09 - $23.82 $139,830 - $194,895
8,182 Added 50.96%
24,237 $424,000
Q4 2023

Feb 13, 2024

SELL
$11.12 - $22.5 $3,958 - $8,010
-356 Reduced 2.17%
16,055 $349,000
Q3 2023

Nov 15, 2023

SELL
$15.16 - $24.7 $8,747 - $14,251
-577 Reduced 3.4%
16,411 $251,000
Q2 2023

Aug 11, 2023

BUY
$22.57 - $29.67 $57,779 - $75,955
2,560 Added 17.74%
16,988 $404,000
Q1 2023

May 15, 2023

BUY
$25.04 - $37.6 $15,249 - $22,898
609 Added 4.22%
15,037 $382,000
Q4 2022

Aug 11, 2023

BUY
$18.78 - $29.74 $71,157 - $112,684
3,789 Added 35.61%
14,428 $421,000
Q4 2022

Feb 13, 2023

BUY
$18.78 - $29.74 $71,157 - $112,684
3,789 Added 35.61%
14,428 $421,000
Q3 2022

Aug 11, 2023

SELL
$10.7 - $25.5 $952 - $2,269
-89 Reduced 0.83%
10,639 $218,000
Q3 2022

Nov 03, 2022

SELL
$10.7 - $25.5 $952 - $2,269
-89 Reduced 0.83%
10,639 $218,000
Q2 2022

Aug 11, 2023

SELL
$9.55 - $19.0 $41,150 - $81,871
-4,309 Reduced 28.66%
10,728 $124,000
Q2 2022

Aug 15, 2022

BUY
$9.55 - $19.0 $102,452 - $203,832
10,728 New
10,728 $124,000

Others Institutions Holding VRDN

About Viridian Therapeutics, Inc.\DE


  • Ticker VRDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,888,900
  • Market Cap $863M
  • Description
  • Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...
More about VRDN
Track This Portfolio

Track Manufacturers Life Insurance Company, The Portfolio

Follow Manufacturers Life Insurance Company, The and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

News

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.